News | 27 May 2021
Cadila Healthcare posts consolidated PAT of Rs. 679 Cr
Cadila Healthcare has reported total income of Rs.15139.4 crores FY 2020-21
Cadila Healthcare has reported total income of Rs.15139.4 crores FY 2020-21
Strides Pharma Science reported total income of Rs.3367.29 crores during FY 2020-21
The company reported net profit for FY21 at Rs. 2,903.8 crore, lower by 23% over last year
Revenue from operations for the year ended March 31, 2021 is ?2,239 crore
With the surge of infections in India in the recent days AmphoTLC will address the country's acute liposomal amphotericin B shortage
The turnover of its NPNC Formulations Division (IKKT Undertaking) for FY 2020-2021 is Rs.21.33 Cr
This marks Glenmark's first synthetic decapeptide injectable approval
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
Posaconazole is a triazole antifungal agent indicated for treating mucormycosis patients
The company has reported total income of Rs.826.40 crores for FY 2020-21
It posted net profit of Rs.188.77 crores for the period ended March 31, 2020.
The company plans to enter the EU markets in FY22
Nanoform and Celanese intend to work on formulation development, leveraging each organization's unique formulation expertise.
First batch produced at Panacea Biotec’s facilities at Baddi will be shipped to the Gamaleya Center for quality control and full scale production of the vaccine is due to start this summer
NATCO Pharmaceuticals, Hyderabad; Alembic Pharmaceuticals, Vadodara; Gufic Biosciences Ltd., Gujarat; Emcure Pharmaceuticals, Pune; and Lyka, Gujarat are new manufacturers
The company reported total income of Rs.455.28 crores during the 12 months period ended March 31, 2021
The product patent has been already filed under fast track approval
Allecra Therapeutics would now either directly or through out license file for NDA of this molecule.
Drop in revenue in the fourth quarter is normal as China is shut down for most of the quarter due to the Chinese New Year holiday
Availability of drugs is being monitored by implementing a three-pronged strategy of supply chain management, demand side management, and affordability.
Subscribe To Our Newsletter & Stay Updated
